Improving cardiovascular risk prediction in metabolic liver disease with a novel biomarker-enhanced model
The integration of liver-specific biomarkers into cardiovascular risk assessment models for MASLD/MASH patients significantly enhances predictive accuracy. The LIVER-ASCVD+ model represents a promising approach to improving clinical decision-making and patient outcomes in MASLD/MASH, warranting further validation.
Authors
- Lars Hegstrom
- Robert G. Gish (ORCID: https://orcid.org/0000-0001-6306-3189)
- Tyler Wagner (ORCID: https://orcid.org/0000-0003-1726-016X)
- Yestle Kim
- Pete Vu
Institutions
- Madrigal Pharmaceuticals (United States) (US)
- Nference (United States) (US)
Publication Details
- Journal
- Current Medical Research and Opinion
- Published
- 2025-11-02
- DOI
- https://doi.org/10.1080/03007995.2025.2606553
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00